A5042034712- HIV/AIDS Research and Interventions
- Pregnancy and Medication Impact
- HIV/AIDS drug development and treatment
- Reproductive Health and Contraception
- Pharmacological Effects and Toxicity Studies
- Sexual function and dysfunction studies
- Breastfeeding Practices and Influences
- Folate and B Vitamins Research
- Adolescent Sexual and Reproductive Health
- HIV, Drug Use, Sexual Risk
- HIV-related health complications and treatments
- Syphilis Diagnosis and Treatment
Infectious Diseases Institute
2019-2024
Makerere University
2019-2024
BackgroundLate initiation of antiretrovirals in pregnancy is associated with increased risk perinatal transmission and higher infant mortality. We report the final 72-week postpartum results for efficacy safety dolutegravir-based compared efavirenz-based regimens mothers infants.MethodsDolPHIN-2 was a randomised, open-label trial. Pregnant women South Africa Uganda aged at least 18 years, untreated but confirmed HIV infection an estimated gestation 28 weeks, initiating antiretroviral therapy...
Abstract Background Rapid reduction in human immunodeficiency virus (HIV) load is paramount to prevent peripartum transmission women diagnosed late pregnancy. We investigated dolutegravir population pharmacokinetics maternal plasma, umbilical cord, breast milk, and infant plasma samples from DolPHIN-1 participants (NCT02245022) presenting with untreated HIV pregnancy (28–36 weeks gestation). Methods Pregnant Uganda South Africa were randomized (1:1) daily (50 mg/d) or efavirenz-based...
We evaluated the pharmacokinetics of double-dose levonorgestrel (LNG) implants to overcome drug-drug interaction with efavirenz-based antiretroviral therapy (ART).We conducted a nonrandomized, open-label, parallel-group, longitudinal pharmacokinetic study among Ugandan women ages 18-45 years. Participants HIV on ART containing efavirenz 600 mg received 300 LNG (Jadelle®, Bayer, New Zealand): 300LNG+ART group. compared our outcomes without using standard dose, 150 implants: 150LNG The implant...
BackgroundConcomitant use of efavirenz-based antiretroviral therapy and a standard-dose etonogestrel contraceptive implant led to 82% lower exposure when compared with women who do not receive therapy. The clinical impact this reduced is supported by retrospective cohort evaluations that demonstrated higher rates unintended pregnancies implants were combined efavirenz. We hypothesized placement 2 in those taking could increase improve measures efficacy.ObjectiveThis study the rate ovulation...
Abstract Around 1.2 million women living with HIV give birth annually, majority of whom will breastfeed their infants while receiving antiretroviral therapy (ART). Lamivudine, a component first‐line ART regimens crosses from maternal plasma to breast milk, measurable concentrations in some breastfed infants. Wide variability plasma‐to‐breast milk transfer has been reported within‐ or across studies, probably due differences sampling framework. This work sought characterize the milk‐to‐plasma...
Abstract Background Pharmacokinetic data are lacking for progestin-releasing subdermal contraceptive implants when used with either rilpivirine- or darunavir/ritonavir-based ART. Objectives To characterize the pharmacokinetics of etonogestrel levonorgestrel administered these ART regimens over 48 weeks. Patients and methods Two separate, parallel, three-group, non-randomized, pharmacokinetic studies evaluated in women receiving darunavir-based compared without HIV (control group)....